Athero Review - Issue 3/2019
Editorial
123
Guidelines
126
A statement of the Committee of the Czech Society for Atherosclerosis on the 2019 ESC/EAS Recommendations for the diagnosis and treatment of dyslipidemia
Michal Vrablík, Jan Piťha, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Zuzana Urbanová Za Výbor Čsat
138
145
The effect of statins on podocytes in nephrotic syndrome
Peter Habara, Marie Claire Šmůlová, Pavla Fialová, Jan Krtil, Karolína Krátká, Ivan Rychlík
153
Dyslipidemia in patients with chronic kidney disease
Magdaléna Dušejovská, Marek Vecka, Ivan Rychlík, Aleš Žák
159
Apolipoprotein L1 – ethnically specific determinant of renal and heart failure
Jaroslav A. Hubáček
clinical studies
162
Observational study of dyslipidemia management in the Czech Republic
Lukáš Zlatohlávek, Michaela Šnejdrlová, Ian Bridges, Romana Šindelářová
171
Lysosomal acid lipase deficiency: one of the possible causes of dyslipidemia and hepatopathy
Eva Tůmová, Michal Vrablík
176
Vitamin D and coronary artery risk detected by computed tomography
Dominik Pella, Claudia Gibarti, Zuzana Pella, Jozef Gonsorčík
181
Ten ways of using ezetimibe, or a brief guide to its use today
Martin Šatný, Michal Vrablík
185
From International Literature
189
Annoucements
191
193
Šobrův den 2019: Lipidologie opět na výsluní
Kristýna Čillíková
Athero Review
2019 Issue 3
Most read in this issue
- Ten ways of using ezetimibe, or a brief guide to its use today
- A statement of the Committee of the Czech Society for Atherosclerosis on the 2019 ESC/EAS Recommendations for the diagnosis and treatment of dyslipidemia
- Specificities of the treatment for vascular system diseases in patients with a chronic renal disease
- Dyslipidemia in patients with chronic kidney disease